NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Study Details
Study Description
Brief Summary
The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
The preclinical study clarified that NKG2D-based CAR-T cells showed strong cytotoxicity against NKG2DL+ cell lines in vitro as well as a therapeutic effect against NKG2DL+ cell xenografts in vivo. In addition, the data also demonstrated the safety of NKG2D-based CAR-T therapy. NKG2D-based CAR-T represent a potentially effective and safety therapeutic approach for patient with relapsed/refractory NKG2DL+ solid tumors. In this trial, the investigators researched the safety of administering NKG2D-based CAR-T which generated with CD8 hinge region and transmembrane region, 4-1BB costimulatory region and CD3 zeta region. The investigators also assessed that disease response was determined within the context of a phase I trial.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Arms NKG2D-based CAR T-cells Injection; Dosage:1-10x10^6/kg, 70ml/time, The CAR-T cells will be administered by i.v. or hepatic portal artery injection over 20-30 minutes Frequency: total one time |
Biological: NKG2D-based CAR T-cells
Autologous genetically modified anti-NKG2DLs CAR transduced T cells
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants with severe cytokine release syndrome(CRS) as a Measure of Safety and Tolerability. [0 to 28 days post infusion]
The severe CRS post KD-025 CAR-T cells treatment will be evaluated and the maximum tolerated dose will be determined.
- Copies numbers of CAR [1 year post infusion]
Copies numbers of CAR in peripheral blood (PB)
Secondary Outcome Measures
- overall survival (OS) [2 years post infusion]
For all subjects, overall survival refers to the period from being included in the test group to death caused by any reason
- Progress Free Survival (PFS) [2 years post infusion]
Progress Free Survival after administration
- Duration of response, (DoR) [2 years post infusion]
Eligibility Criteria
Criteria
Inclusion criteria:
-
Men or women≥18 years old,
-
Patient with NKG2DL+ cell tumors confirmed by pathology and histology,
-
Fail or unwilling to receive first-line treatment,
-
Disease must be measurable according to the corresponding guidelines,
-
Main organs function normally and meet following requirements:
Routine blood index(No Blood transfusion within 14 days) 1)HB≥90g/L; 2)ANC≥1.5×109/L; 3)PLT≥75×109/L; Serum biochemicals index 1) BIL <1.5 upper normal limit (ULN); 2) ALT and AST<2.5×ULN; In the case of liver metastasis, ALT and AST<5×ULN; 3) Serum Cr≤1×ULN, endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula); 4) ECOG physical condition score: 0-2
-
Expected survival time ≥3 months,
-
Patient with adequate bone marrow reserve, hepatic and renal functions,
-
No other uncontrolled diseases such as lung, kidney and liver infection before enrollment,
-
Women of child-bearing age must undergo a negative pregnancy test (serum or urine) within 7 days prior to enrollment and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last dose; men should agree to contraception during the observation period and within 8 weeks of the last dose,
-
Patients voluntarily participated in this trial and sign the informed consent form,
-
Patients with compliance and expected to follow up the efficacy and adverse reactions as required by the protocol.
Exclusion criteria:
-
Pregnant or lactating women,
-
Patients who need to use systemic steroids at the same time,
-
Under following treatment conditions currently: 1) during the other anti- tumor clinical observation period within 14 days before blood collection; 2) patient has not recovered from acute side effects of the previous treatment;
-
Receive radiotherapy within 4 weeks before enrollment,
-
Patients who received any other cell therapy before,
-
Patients with unqualified T cell amplification efficiency,
-
Uncontrolled symptoms or other illnesses, including but not limited to infection, congestive heart failure, unstable angina, arrhythmia, psychosis,
-
Patients with severe acute allergic reactions,
-
Patients who have received other cell therapies,
-
Other serious conditions that may limit patient's participation in the study.
Detailed disease specific criteria exist and can be discussed with contacts listed below.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Affiliated hospital of jiujiang university | Jiujiang | Jiangxi | China | 332000 |
Sponsors and Collaborators
- Jiujiang University Affiliated Hospital
- KAEDI
Investigators
- Study Director: Changchun Cai, Affiliated hospital of jiujiang university
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- JiujiangUH